Supratek Pharma Inc.
Records under this name other than patents Supratek Pharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,703,964 | Bendamustine cyclopolysaccharide compositions Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,389,558 | Bendamustine amphiphilic anionic compositions Formerly held In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US 8,436,032 | Bendamustine cyclopolysaccharide compositions Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,383,663 | Bendamustine anionic-catioinic cyclopolysaccharide compositions Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,919,053 | Cabazitaxel composition Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,148,338 | Doxorubicin formulations for anti-cancer use Formerly held Lapsed on the fee record Ended Apr 3, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 3, 2024 | From the USPTO record |
| US 6,277,410 | Copolymer compositions for oral delivery Term ended Term ended Feb 6, 2018 · From the USPTO record | Term ended | Term ended Feb 6, 2018 | From the USPTO record |
| US 6,440,743 | Methods of using polynucleotide compositions Lapsed on the fee record Ended Aug 27, 2014 · From the USPTO record | Lapsed on the fee record | Ended Aug 27, 2014 | From the USPTO record |
| US 7,772,255 | Method of treating tumors with azaxanthones Lapsed on the fee record Ended Aug 10, 2014 · From the USPTO record | Lapsed on the fee record | Ended Aug 10, 2014 | From the USPTO record |
| US 6,359,054 | Polynucleotide compositions for intramuscular administration Lapsed on the fee record Ended Mar 19, 2014 · From the USPTO record | Lapsed on the fee record | Ended Mar 19, 2014 | From the USPTO record |